Cite
HARVARD Citation
Hartrampf, P. et al. (2022). Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy. Prostate. 82 (14), pp. 1406-1412. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Hartrampf, P. et al. (2022). Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy. Prostate. 82 (14), pp. 1406-1412. [Online].